

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRET  
04 AUG 12**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name  Genzyme Corporation			
2. Address <input type="checkbox"/> Check if different than previously reported  1020 Nineteenth Street, NW, Suite 550, Washington, DC 20036			
3. Principal Place of Business (if different from line 2)  City: Cambridge State/Zip (or Country) MA 02142			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Mary McGrane	(202) 296-3280		16054-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
		30257000	

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1-June 30)  OR Year End (July 1-December) 
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbying /

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p align="center"><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>860,000.00</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(c) Internal Revenue Code</p> <p><input checked="" type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>
---	--

Signature \_\_\_\_\_

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

LD-2 (REV. 6/98)

PAG

Registrant Name Genzyme Corporation (16054-12)Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

a) Medicare Prescription Drug Benefit:

Implementation of issues associated with P.L. 108-173, including the new payment system for hospital outpatient departments and reimbursement for orphan drugs

b) Medicare payment for administration of Fabrazyme during dialysis for ESRD patients

17. House (s) of Congress and Federal agencies contacted

 C

- a) United States Senate  
 United States House of Representatives  
 Department of Health and Human Services
- b) Department of Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

 Check if NoneSignature  Date 5 August 2004Printed Name and Title Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation (16054-12)

Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Oppose creation of a system to approve generic biologics

17. House (s) of Congress and Federal agencies contacted

Check if None

United States Senate  
United States House of Representatives  
Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 5 August 2004

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations



Registrant Name Genzyme Corporation (16054-12)

Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Oppose importation of drugs from outside the United States

- H.R. 616 – “Prescription Drug Affordability Act”
- H.R. 847 – “Preserving Access to Safe, Affordable Canadian Medicines Act of 2003”
- H.R. 2717 – “Affordable Medicine Safety and Access Act”
- H.R. 2427 – “Pharmaceutical Market Access Act of 2003”
- H.R. 2491 – “Greater Access to Affordable Pharmaceuticals Act”
- H.R. 2497 – “Prescription Drug Parity for Americans Act”
- H.R. 2629 – “New Aid for Trustworthy, Affordable Drugs Act (NAFTA Drugs Act)”
- H.R. 2769 – “Save Our Seniors Act of 2003”
- S. 7 – “Prescription Drug Benefit and Cost Containment Act of 2003”
- S. 1781 – “Pharmaceutical Market Access Act of 2003”
- S. 2137 – “Pharmaceutical Market Access Act of 2003”
- S. 2307 – “Reliable Entry for Medicines at Everyday Discounts through Importation with Effective Safeguards Act of 2004”
- S. 2328 – “Pharmaceutical Market Access and Drug Safety Act of 2004”

17. House (s) of Congress and Federal agencies contacted  Check if None

United States Senate  
United States House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mary McGrane	
Sara Froelich	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date 5 August 2004

Printed Name and Title Mary McGrane, Senior Vice President, Government Relations

